GridAI Technologies (GRDX) Non Operating Interest Expenses (2015 - 2025)
GridAI Technologies' (GRDX) quarterly Non Operating Interest Expenses came in at $17902.0 in Q1 2025, down 72.96% on a YoY basis from $66202.0 in Q1 2024, and up 7917.47% quarter-over-quarter from -$229.0 in Q3 2024.
Powered by 
Analysis
GridAI Technologies (GRDX) Non Operating Interest Expenses (2015 - 2025) Analysis & Trends
GridAI Technologies (GRDX) has reported Non Operating Interest Expenses for 11 consecutive years, with $17902.0 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Non Operating Interest Expenses fell 72.96% year-over-year to $17902.0; the trailing twelve-month figure through Mar 2025 stood at $83657.0 (up 2.58% YoY), and the FY2023 full-year result was $22463.0, up 41.46% from the prior year.
- Non Operating Interest Expenses climbed to $17902.0 in Q1 2025 per GRDX's latest filing, from -$229.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $66202.0 in Q1 2024 and bottomed at -$229.0 in Q3 2024.
- Historically, Non Operating Interest Expenses has averaged $8444.2 across 5 years, with a median of $4095.5 in 2022.
- The widest YoY moves for Non Operating Interest Expenses: up 636.64% in 2024, down 122.43% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at $2395.0 in 2021, then soared by 158.58% to $6193.0 in 2022, then jumped by 51.06% to $9355.0 in 2023, then plunged by 102.45% to -$229.0 in 2024, then surged by 7917.47% to $17902.0 in 2025.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $17902.0, -$229.0, and -$218.0 for Q1 2025, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.12 Bn | 192.13 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.16 Bn | 176.98 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.95 Bn | 73.96 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.36 Bn | 55.18 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.01 Bn | 29.70 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.96 Bn | 30.67 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.25 Bn | 29.25 Bn | 1.16 Mn | - |
| 10 | GridAI Technologies | 19.39 Mn | 19.39 Mn | -36,514.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 17,902.00 |
| Sep 30, 2024 | -229.00 |
| Jun 30, 2024 | -218.00 |
| Mar 31, 2024 | 66,202.00 |
| Dec 31, 2023 | 9,355.00 |
| Sep 30, 2023 | 1,021.00 |
| Jun 30, 2023 | 4,973.00 |
| Mar 31, 2023 | 8,987.00 |
| Dec 31, 2022 | 6,193.00 |
| Sep 30, 2022 | 863.00 |
| Jun 30, 2022 | 3,218.00 |
| Mar 31, 2022 | 5,605.00 |
| Dec 31, 2021 | 2,395.00 |
| Sep 30, 2021 | 742.00 |
| Jun 30, 2021 | 2,954.00 |
| Mar 31, 2021 | 5,144.00 |
| Dec 31, 2020 | 2,197.00 |
| Sep 30, 2020 | 1.20 Mn |
| Jun 30, 2020 | 2.30 Mn |
| Mar 31, 2020 | 2.33 Mn |